Albumin-corrected anion gap and mortality risk in cardiorenal syndrome: Insights from a nationally representative cohort study
Hongman Li, Xing Huang, Shengyong Si, Zhijing Li, Chun Zhao, Xue Zhao, Mengdie Liu, Yuan Deng, Xue Zhao · 2026
Read Albumin-corrected anion gap and mortality risk in cardiorenal syndrome: Insights from a nationally representative cohort study by Hongman Li, Xing Huang, Shengyong Si, Zhijing Li, Chun Zhao, Xue Zhao, Mengdie Liu, Yuan Deng, Xue Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13313717.txt.
Description
Hongman Li and co-authors test, in a 2026 cohort study, whether a corrected blood chemistry measure can forecast death in cardiorenal syndrome, where heart and kidney failure feed each other. The albumin-corrected anion gap adjusts the standard acid measure for low albumin, common in these patients. Drawing on a nationally representative American survey spanning 2005 to 2018, the team followed 1,783 patients with the syndrome for a median of 72 months.
During follow-up, 859 patients died, about 36 percent of them from cardiovascular causes. Each step up in the corrected gap carried a hazard ratio of 1.14 for both overall and cardiovascular death in the adjusted models, and spline analysis showed a straight dose-response climb rather than a threshold effect. The pattern held across demographic and clinical subgroups. The authors promote the measure as a cheap, universally available risk marker for nephrology practice, pending confirmation in prospective cohorts.
Catalog record
| CREATOR | Hongman Li, Xing Huang, Shengyong Si, Zhijing Li, Chun Zhao, Xue Zhao, Mengdie Liu, Yuan Deng, Xue Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |